Neurologix has announced efficacy results from the Phase II clinical trial of gene therapy agent NLX-P101, used for the treatment of Parkinson’s disease.
The trial included 45 subjects with moderate to advanced Parkinson’s disease and demonstrated that treatment with NLX-P101 improved the primary motor symptoms of Parkinson’s disease in patients.
Go deeper with GlobalData
Neurologix scientific co-founder Matthew J During said the results demonstrated that treatment with gene therapy agent showed the clinically meaningful improvement and durability over the long-term.
Parkinson’s disease is a progressive and debilitating neurodegenerative disorder that affects the control of bodily movement.
NLX-P101 modulates the activity of the STN, which is overactive in patients with Parkinson’s disease, by restoring GABA, a neurotransmitter important in STN function.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
